LATEST ARTICLES

8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities...

CIRM approves $6 million in funding for UCI Researchers to study new treatment for...

Following a California Institute for Regenerative Medicine (CIRM) Independent Citizens Oversight Committee meeting held last week, University of California, Irvine (UCI) researchers learned they...

ALBORADA Drug Discovery Institute identifies advanced Huntington’s leads using BioAscent’s Compound Cloud library

BioAscent’s unique on-demand compound library, Compound Cloud, has been used by the ALBORADA Drug Discovery Institute for virtual screening and to progress promising leads against a novel Huntington’s...

Expert-based clinical guidelines focus on behavioral symptoms in Huntington’s disease

Clinicians treating patients with HD are often not trained to recognize or treat neuropsychiatric symptoms of the disease, according to new guidelines published in...

Huntington’s disease goes viral as UniQure inches ahead in gene therapy race

FDA grants “Investigational New Drug” status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntington’s Disease patients Dutch-American company uniQure has received...

First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington’s...

First of 4+ Ionis programs expected to advance to pivotal studies this yearIonis earns $35 million milestone payment CARLSBAD, Calif., Jan. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:...